Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of Dasatinib in Advanced Melanoma.

Trial Profile

A Phase 2 Study of Dasatinib in Advanced Melanoma.

Phase of Trial: Phase II

Latest Information Update: 30 Jun 2014

At a glance

  • Drugs Dasatinib (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Apr 2013 Planned End Date changed from 1 May 2008 to 1 May 2010 as reported by ClinicalTrials.gov.
    • 15 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 18 Jun 2008 Trial identifier UMN2007UC009 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top